Elizabeth B Claus1, Peter M Black. 1. Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, PO Box 208034, New Haven, CT 06520, USA. elizabeth.claus@yale.edu
Abstract
BACKGROUND: Detailed population-based estimates of long-term survival as well as patterns of care for patients with low-grade gliomas examined by age at diagnosis, gender, and race have not been widely available. METHODS: Time to death was examined among 2009 individuals diagnosed with a supratentorial low-grade glioma and reported to the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute from 1973-2001 using Kaplan-Meier estimation. A Cox proportional hazards model was used to assess the effect of age at diagnosis, race, gender, histology, anatomic location within the brain, first course of treatment, and year of diagnosis upon this risk. RESULTS: The cumulative 5-, 10-, 15- and 20-year survival rates among all individuals initially diagnosed with a supratentorial low-grade glioma were 59.9% (95% confidence interval [95% CI], 57.6-62.2); 42.6% (95% CI, 39.9-45.2); 31.9% (95% CI, 29.0-34.8); and 26.0% (95% CI, 22.7-29.2), respectively. Improved survival was significantly associated with female gender (hazard ratio [HR], 0.84; 95% CI, 0.74-0.95), younger age, white race (HR, 0.70; 95% CI, 0.54-0.93), histology, and later year of diagnosis. Surgical treatment was associated with increased survival. The use of radiation therapy as a first course of treatment for these lesions has significantly decreased over time with the majority of patients receiving only surgery as a first course of treatment. CONCLUSIONS: Data for patients diagnosed with low-grade gliomas revealed increasing survival times over the past 25 years with a subset of patients surviving for decades. Differences in survival by race, gender, histology, and first course of treatment were appreciated. These data suggested that the clinical course of low-grade glioma for some patients may be more encouraging than previously perceived and that the identification of this group of patients may allow refinement of current treatment protocols. (c) 2006 American Cancer Society.
BACKGROUND: Detailed population-based estimates of long-term survival as well as patterns of care for patients with low-grade gliomas examined by age at diagnosis, gender, and race have not been widely available. METHODS: Time to death was examined among 2009 individuals diagnosed with a supratentorial low-grade glioma and reported to the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute from 1973-2001 using Kaplan-Meier estimation. A Cox proportional hazards model was used to assess the effect of age at diagnosis, race, gender, histology, anatomic location within the brain, first course of treatment, and year of diagnosis upon this risk. RESULTS: The cumulative 5-, 10-, 15- and 20-year survival rates among all individuals initially diagnosed with a supratentorial low-grade glioma were 59.9% (95% confidence interval [95% CI], 57.6-62.2); 42.6% (95% CI, 39.9-45.2); 31.9% (95% CI, 29.0-34.8); and 26.0% (95% CI, 22.7-29.2), respectively. Improved survival was significantly associated with female gender (hazard ratio [HR], 0.84; 95% CI, 0.74-0.95), younger age, white race (HR, 0.70; 95% CI, 0.54-0.93), histology, and later year of diagnosis. Surgical treatment was associated with increased survival. The use of radiation therapy as a first course of treatment for these lesions has significantly decreased over time with the majority of patients receiving only surgery as a first course of treatment. CONCLUSIONS: Data for patients diagnosed with low-grade gliomas revealed increasing survival times over the past 25 years with a subset of patients surviving for decades. Differences in survival by race, gender, histology, and first course of treatment were appreciated. These data suggested that the clinical course of low-grade glioma for some patients may be more encouraging than previously perceived and that the identification of this group of patients may allow refinement of current treatment protocols. (c) 2006 American Cancer Society.
Authors: Nicolas R Smoll; Oliver P Gautschi; Bawarjan Schatlo; Karl Schaller; Damien C Weber Journal: Neuro Oncol Date: 2012-07-06 Impact factor: 12.300
Authors: Nitin Mukerji; Desiderio Rodrigues; Gill Hendry; Peter R C Dunlop; Fiona Warburton; Philip J Kane Journal: J Neurooncol Date: 2007-11-17 Impact factor: 4.130
Authors: Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan Journal: J Neurooncol Date: 2007-05-26 Impact factor: 4.130
Authors: Erica H Bell; Peixin Zhang; Barbara J Fisher; David R Macdonald; Joseph P McElroy; Glenn J Lesser; Jessica Fleming; Arup R Chakraborty; Ziyan Liu; Aline P Becker; Denise Fabian; Kenneth D Aldape; Lynn S Ashby; Maria Werner-Wasik; Eleanor M Walker; Jean-Paul Bahary; Young Kwok; H Michael Yu; Nadia N Laack; Christopher J Schultz; Heidi J Gray; H Ian Robins; Minesh P Mehta; Arnab Chakravarti Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Hanwen Bai; Akdes Serin Harmancı; E Zeynep Erson-Omay; Jie Li; Süleyman Coşkun; Matthias Simon; Boris Krischek; Koray Özduman; S Bülent Omay; Eric A Sorensen; Şevin Turcan; Mehmet Bakırcığlu; Geneive Carrión-Grant; Phillip B Murray; Victoria E Clark; A Gulhan Ercan-Sencicek; James Knight; Leman Sencar; Selin Altınok; Leon D Kaulen; Burcu Gülez; Marco Timmer; Johannes Schramm; Ketu Mishra-Gorur; Octavian Henegariu; Jennifer Moliterno; Angeliki Louvi; Timothy A Chan; Stacey L Tannheimer; M Necmettin Pamir; Alexander O Vortmeyer; Kaya Bilguvar; Katsuhito Yasuno; Murat Günel Journal: Nat Genet Date: 2015-11-30 Impact factor: 38.330